Beyond medication prescription as performance measures: Optimal secondary prevention medication dosing after acute myocardial infarction

Journal of the American College of Cardiology

Volumn 62, Issue 19, 2013, Pages 1791-1801

  Arnold, Suzanne V ^a,b   Spertus, John A ^a,b   Masoudi, Frederick A ^c   Daugherty, Stacie L ^c   Maddox, Thomas M ^d   Li, Yan ^a   Dodson, John A ^e   Chan, Paul S ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

myocardial infarction; performance measures; secondary prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOLOGIST; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG UNDERDOSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ACEI; ACUTE MYOCARDIAL INFARCTION; AMI; ANGIOTENSIN II RECEPTOR BLOCKER; ANGIOTENSIN-CONVERTING ENZYME INHIBITOR; ARB; CI; CONFIDENCE INTERVAL; LDL-C; LEFT VENTRICULAR; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; LV; MYOCARDIAL INFARCTION; ODDS RATIO; OR; PERFORMANCE MEASURES; SBP; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES;

EID: 84886818333     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.04.102     Document Type: Article

References (32)

1. H.M. Krumholz, J.L. Anderson, and B.L. Bachelder ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction) developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine J Am Coll Cardiol 52 2008 2046 2099
2. E.D. Peterson, M.T. Roe, and J. Mulgund Association between hospital process performance and outcomes among patients with acute coronary syndromes JAMA 295 2006 1912 1920
3. M.R. Bristow, E.M. Gilbert, W.T. Abraham MOCHA Investigators Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure Circulation 94 1996 2807 2816
4. H. Svanström, B. Pasternak, and A. Hviid Association of treatment with losartan vs candesartan and mortality among patients with heart failure JAMA 307 2012 1506 1512
5. M. Packer, P.A. Poole-Wilson, and P.W. Armstrong Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation 100 1999 2312 2318
6. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
7. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
8. R.M. Werner, and E.T. Bradlow Relationship between Medicare's hospital compare performance measures and mortality rates JAMA 296 2006 2694 2702
9. G.C. Fonarow, W.T. Abraham, and N.M. Albert Association between performance measures and clinical outcomes for patients hospitalized with heart failure JAMA 297 2007 61 70
10. S.W. Glickman, F.S. Ou, and E.R. DeLong Pay for performance, quality of care, and outcomes in acute myocardial infarction JAMA 297 2007 2373 2380
11. J.A. Spertus, E. Peterson, J.S. Rumsfeld, P.G. Jones, C. Decker, and H. Krumholz The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) - evaluating the impact of myocardial infarction on patient outcomes Am Heart J 151 2006 589 597
12. S.V. Arnold, P.S. Chan, and P.G. Jones Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry Circ Cardiovasc Qual Outcomes 4 2011 467 476
13. K. Kroenke, R.L. Spitzer, and J.B. Williams The PHQ-9: validity of a brief depression severity measure J Gen Intern Med 16 2001 606 613
14. K.A. Eagle, M.J. Lim, and O.H. Dabbous A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
15. T.R. Pedersen, O. Faergeman, and J.J. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
16. J.K. Lunceford, and M. Davidian Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study Stat Med 23 2004 2937 2960
17. S.A. Murphy, C.P. Cannon, and S.D. Wiviott Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials) Am J Cardiol 100 2007 1047 1051
18. M.R. Bristow, J.B. O'Connell, E.M. Gilbert Bucindolol Investigators Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy Circulation 89 1994 1632 1642
19. H.V. Barron, S. Viskin, and R.J. Lundstrom Beta-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization Arch Intern Med 158 1998 449 453
20. L.K. Newby, N.M. LaPointe, and A.Y. Chen Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease Circulation 113 2006 203 212
21. J.M. Kramer, B. Hammill, and K.J. Anstrom National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance Am Heart J 152 2006 454.e1 454.e8
22. Z. Yang, A. Olomu, W. Corser, D.R. Rovner, and M. Holmes-Rovner Outpatient medication use and health outcomes in post-acute coronary syndrome patients Am J Manag Care 12 2006 581 587
23. Y. Bi, R. Gao, and A. Patel Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study Am Heart J 157 2009 509 516.e1
24. S. Viskin, I. Kitzis, and E. Lev Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice J Am Coll Cardiol 25 1995 1327 1332
25. C. Melloni, B.R. Shah, and F.S. Ou Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry Am Heart J 160 2010 1121 1129 1129.e1
26. J.S. Saczynski, D. Lessard, and F.A. Spencer Declining length of stay for patients hospitalized with AMI: impact on mortality and readmissions Am J Med 123 2010 1007 1015
27. L.S. Phillips, W.T. Branch, and C.B. Cook Clinical inertia Ann Intern Med 135 2001 825 834
28. P. Ferrari, L. Hess, A. Pechere-Bertschi, F. Muggli, and M. Burnier Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study J Hypertens 22 2004 1221 1229
29. D.C. Ziemer, C.D. Miller, and M.K. Rhee Clinical inertia contributes to poor diabetes control in a primary care setting Diabetes Educ 31 2005 564 571
30. D. Peikes, A. Chen, J. Schore, and R. Brown Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials JAMA 301 2009 603 618
31. D.C. Ziemer, J.P. Doyle, and C.S. Barnes An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8 Arch Intern Med 166 2006 507 513
32. P.S. Chan, W.J. Oetgen, and D. Buchanan Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program J Am Coll Cardiol 56 2010 8 14